Gilead Amends Agreement with Galapagos for Development and Commercialization of Jyseleca (filgotinib)

Shots:

• Following the FDA Type A meeting, Gilead will not pursue the approval of Jyseleca for RA in the US. Galapagos will be solely responsible in EU for Jyseleca (200/100mg) in RA and UC + all future indications for which Gilead will receive royalties on EU sales initiating in 2024
• Galapagos to receive $194.6M, which will be split b/w $133.7M in 2021 & $60.8M in 2022 for the ongoing development and accelerated commercial buildout in the EU
• Additionally, Galapagos will assume responsibility for ongoing clinical trials evaluating filgotinib in RA. Gilead will retain commercial rights for filgotinib outside the EU, including in Japan where filgotinib has recently been approved and is co-marketed with Eisai

Click here ­to­ read full press release/ article | Ref: GlobeNewswire | Image: Canva